ClinicalTrials.gg
CompletedNCT02670642NEEDUpdated Feb 2, 2016

Open, Randomised, Multi-center Study of on Demand Versus Continuous Esomeprazole Treatment in Patient With GERD

A Phase 3 interventional study of Esomeprazole in Gastroesophageal Reflux, sponsored by AstraZeneca. Completed at 60 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-02-02.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
877
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies testing esomeprazole in Gastroesophageal Reflux — 1 open to participants now, 1 under way, none of them phase 3. Esomeprazole · Gastroesophageal Reflux.

Enrollment
8th of 66
877 · median 125
Started
2001
with 3 others
Phase 3
15 of 67
none open now
Registered
56th of 67
by date
Lead sponsor
36 of 67
AstraZeneca

Among the 67 studies testing esomeprazole in Gastroesophageal Reflux, this one is the 8th largest by enrollment of the 66 interventional ones that give a count, is one of 4 that started in 2001, is one of 15 in phase 3, and was the 56th registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

1 of the 67 studies testing esomeprazole in Gastroesophageal Reflux is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About esomeprazole

Esomeprazole: first FDA approval 2001 (NEXIUM), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing esomeprazole in Gastroesophageal Reflux, or all of them as a file.
02

Study summary

The purpose of this study is to compare on demand with continuous treatment of endoscopy negative subjects with gastroesophageal reflux disease (GERD), with esomeprazole 20-mg once daily, with regards to willingness to continue in the study as a result of satisfactory treatment over a six-month long term management period, after initial symptom relief.

03

Conditions studied

  • Gastroesophageal Reflux
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Symptoms suggestive of GERD, with heartburn as their predominant symptom (described as a burning feeling, rising from the stomach or lower part of the chest up towards the neck), for longer than 6 months.
  • Heartburn occurring for 4 days or more during the last 7 days prior to endoscopy. Or, if PPI treatment has been started within the last 7 days prior to endoscopy, then heartburn occurring for 4 days or more during the last 7 days prior to start of PPI treatment
  • Male or female, at least 18 years of age (for Austria, at least 19 years of age)
  • Have given written
  • Ability to read and write (literate)
  • 7 symptom free (from heartburn) days in the last week prior to randomisation (day of visit not included)

Exclusion criteria

Exclusion Criteria:

  • Documented esophageal mucosal break
  • History of esophageal, gastric or duodenal surgery, except closure and oversewing of an ulcer
  • Chronic or recurrent abdominal pain associated with a chronic or recurrent bowel disturbance and/or bloating, that in the opinion of the investigator is likely to be due to irritable bowel syndrome or two or more of the following criteria:

    • Symptoms relieved by defecation
    • Symptoms associated with change in frequency of stools
    • Symptoms associated with change in form of stools
  • Any significant "alarm symptoms" such as unintentional weight loss, haematemesis melaena, jaundice or any other sign indicating serious or malignant disease.
  • Subjects with current or historical evidence of the following diseases/conditions

    • Zollinger Ellison syndrome
    • Primary esophageal motility disorder(s) i.e. achalasia, scleroderma, esophageal spasm
    • Complications of GERD such as esophageal stricture, ulcer and/or macroscopic Barrett's metaplasia (longer than 3 centimetres) or significant dysplastic changes in the esophagus
    • Evidence of upper gastrointestinal at the screening endoscopy
    • Gastric and/or duodenal ulcers within the last 2 years
    • Malabsorption
    • Malignancy, or significant cardiovascular, pulmonary, renal, pancreatic or liver disease as judged by the investigator
    • Unstable diabetes mellitus. Stable diabetes controlled on diet, oral agents or insulin is acceptable
    • Cerebrovascular disease, such as cerebral ischemia, infarction, haemorrhage or embolus
  • Subjects using a PPI for more than 10 days in the last 28 days, prior to endoscopy
  • Use of PPIs for more than 5 days in the last 7 days prior to endoscopy
  • Subjects using daily H2-receptor antagonist, prokinetics recommended in the treatment of reflux symptoms or sucralfate during the 2 weeks prior to endoscopy and between the endoscopy and visit 1 and throughout the study
  • Need for continuous concurrent therapy with

    • NSAIDs (including selective COX II antagonists, salicylates (unless\<165 mg daily for cardiovascular prophylaxis)
    • anticholinergics
    • prostaglandin analogues
    • phenytoin
    • ketoconazole
    • itraconazole
    • warfarin and other vitamin K antagonists
  • Pregnancy or lactation. Women of must maintain effective during the study period as judged by the investigator (for Austria: Women of child-bearing potential may only be included when their pregnancy status is assessed by the investigator prior to entry and then at monthly basis. For South-Africa and Spain:

Women of child-bearing potential may only be included when their pregnancy status is assessed by the investigator prior to endoscopy)

  • Use of any other compound 28 days prior to start and during the study
  • Requirement of an interpreter (illiterate)
  • Alcohol and/or drug abuse or any condition associated with poor compliance, including expected non-co-operation, as judged by the investigator
  • Previous participation in this study
  • to study drugs, e.g. known or suspected allergy to esomeprazole and any other constituents of the formulation. Known to substituted benzimidazole
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
877 participants (actual)

Study arms

  • Experimental
    On demand 20 mg esomeprazole

    On demand treatment with 20-mg esomeprazole once daily when needed

    Drug: Esomeprazole

  • Active comparator
    Continuous 20 mg esomeprazole

    Continuous treatment with 20 mg esomeprazole once daily

    Drug: Esomeprazole

Interventions

06

What researchers measure

Primary outcomes

  1. Difference between the proportion of patients who discontinued on-demand esomeprazole treatment versus continuous esomeprazole treatment due to unsatisfactory treatment as determined by the investigator in consultation with the patient

    Compare on demand (taken as needed by the patient to adequately control their reflux disease) with continuous treatment of endoscopy negative subjects with gastroesophageal reflux disease (GERD), with esomeprazole 20-mg once daily, with regards to willingness to continue in the study as a result of satisfactory treatment over a six-month long term management period, after initial symptom relief

    Time frame: 6 months

Secondary outcomes

  1. Reasons for discontinuation of on-demand or continuous esomeprazole treatment assessed by investigator-completed questionnaire at clinical visits

    Time frame: 6 months

  2. Mean number of esomeprazole tablets taken measured using the Medical Event Monitoring System (MEMS) container (date and time of use recorded)

    Time frame: 6 months

  3. Change from baseline in impact of reflux symptoms on health-related quality of life using pre-specified dimensions of the Gastrointestinal Symptom Rating Scale (GSRS) questionnaire

    Time frame: 6 months

  4. Difference between the proportion of patients reporting treatment satisfaction with on-demand versus continuous esomeprazole treatment assessed by standard patient-completed electronic questionnaire at clinical visits and premature discontinuation

    Time frame: 6 months

  5. Frequency of adverse events and assessment of hematology (hemoglobin, leukocytes, thrombocytes) and clinical chemistry (creatinine, alkaline phosphate, aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transferase, total bilirubin)

    Time frame: 6 months

  6. Individual patterns of esomeprazole tablet usage measured using the Medical Event Monitoring System (MEMS) container (date and time of use recorded)

    Time frame: 6 months

  7. Change from baseline in impact of reflux symptoms on health-related quality of life using pre-specified dimensions of the Quality Of Life in Reflux And Dyspepsia (QOLRAD) questionnaire

    Time frame: 6 months

07

Study locations

60 sites
  • A.ö.Landeskrankenhaus Feldbach
    Feldbach, A-8330, Austria
  • A.ö. Landeskrankenhaus Kittsee
    Kittsee, A-2421, Austria
  • Spitalverbund Landeskrankenhaus
    Knittelfeld, A-8720, Austria
  • Krankenhaus der Stadt Wien
    Wien, A-1030, Austria
  • Hanusch Hospital
    Wien, A-1140, Austria
  • A.ö. Krankenhaus Zell am See
    Zell am See, A-5700, Austria
  • 36 boulevard Gambetta
    Ales, 30100, France
  • 84 rue Gustave Colin
    Arras, 62000, France
  • 15 rue Michelet
    Belfort, 90000, France
  • 30 boulevard du Président John Kennedy
    Beziers, 34500, France
  • 10 avenue Villeneuve
    Cagnes Sur Mer, 06800, France
  • 13 rue Roquebillière
    Cannes La Bocca, 06150, France
  • 91 rue de Paris
    Charenton Le Pont, 94220, France
  • 62 rue Bonnabaud
    Clermont Ferrand, 63000, France
  • 17 villa du Petit Parc
    Creteil, 94000, France
  • 24 quai Saint Maurand
    Douai, 59500, France
  • 3 place du Marché Couvert
    Dreux, 28100, France
  • Clinique Saint Vincent
    Epernay, 51205, France
  • 7 rue Parmentier
    Epinal, 88000, France
  • Place du Postillon
    Issoire, 63500, France
  • 60 rue Jean Bart
    Lille, 59000, France
  • 81 avenue du Teil
    Montelimar, 26200, France
  • 9 square de Liège
    Nancy, 54500, France
  • 6 avenue du Maréchal Juin
    Narbonne, 11100, France
  • 74 avenue Paul Doumer
    Paris, 75016, France
  • 45bis rue d.Elbeuf
    Rouen, 76000, France
  • 64 boulevard Marcel Sembat
    Saint Denis, 93200, France
  • 31 rue Henri Maréchal
    Saint Priest, 69800, France
  • 201 boulevard Robespierre
    Talence, 33401, France
  • 4 rue Berlioz
    Velizy Villacoublay, 78140, France
  • 20 rue de la Glacière
    Vitry Sur Seine, 94400, France
  • 68 avenue Paul Vaillant Couturier
    Vitry Sur Seine, 94400, France
  • Wartburgstraße 19
    Berlin, 10825, Germany
  • Carl Gustav Carus der Tecnischen Universität
    Dresden, D-010307, Germany
  • Finkenstraße 31
    Freising, 85356, Germany
  • Reichenbacher Str. 106 a
    Görlitz, 02827, Germany
  • Frankenwaldklinik
    Kronach, 96317, Germany
  • Gemeinschaftspraxis
    Köln, 51065, Germany
  • Genovevastraße 5
    Köln, 51065, Germany
  • Buchentorstr. 16
    Lienen, 49536, Germany
  • Hammer Str. 108
    Münster, 48153, Germany
  • Albersloher Weg 455
    Münster, 48167, Germany
  • Am Bahnhof 3
    Oelde, 59302, Germany
  • Rudolf-Breitscheid-Str. 56
    Potsdam, 14482, Germany
  • Musikantenweg 3
    Ribnitz, 18311, Germany
  • Friedensstr. 14
    Wolmirstedt, 39326, Germany
  • Gastroenterology Clinic, G73, Department of Internal Medicine, Universitas Hospital
    Bloemfontein, South Africa
  • Burnside House, Room 1
    Cape Town, South Africa
  • Gastroenterology Clinic, E23, Groote Schuur Hospital Observatory
    Cape Town, South Africa
  • Gastroenterology Clinic, Parorama Medi-Clinic
    Cape Town, South Africa
  • Gastroenterology Unit, Room C78, Tygerberg Hospital
    Cape Town, South Africa
  • Unitas Hospital Lyttleton
    Centurion, South Africa
  • Gastroenterology Clinic, Parklands Medical Centre
    Durban, South Africa
  • Gastroenterology Clinic, Milpark Hospital
    Johannesburg, South Africa
  • Gastroenterology Unit, Chris Hani Baragwanath Hospital
    Johannesburg, South Africa
  • Centro Médico Teknon
    Barcelona, 08022, Spain
  • Hospital General de Guadalajara
    Guadalajara, 19009, Spain
  • Hospital Central de Asturias
    Oviedo, 33006, Spain
  • Hospital Clínico Universitario
    Santiago de Compostela, 15706, Spain
  • Hospital Virgen Macarena
    Sevilla, 41071, Spain
08

References and documents

Publications

  • Bayerdorffer E, Bigard MA, Weiss W, Mearin F, Rodrigo L, Dominguez Munoz JE, Grundling H, Persson T, Svedberg LE, Keeling N, Eklund S. Randomized, multicenter study: on-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease. BMC Gastroenterol. 2016 Apr 14;16:48. doi: 10.1186/s12876-016-0448-x. PubMed 27080034 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2001, a primary completion of Nov 2002 and a completion of Nov 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2015
First posted
Feb 2, 2016
Start
Aug 2001
Primary completionActual
Nov 2002
CompletionActual
Nov 2002
Last update
Feb 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02670642
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 2, 2016
Start date
Aug 2001
Primary completion
Nov 2002
Completion
Nov 2002
Last update
Feb 2, 2016

Study contacts

Ekkehard Bayerdörffer, MD
principal investigator · University Hospital Carl-Gustav-Carus, Medical Clinic and Policlinic I, Fetscherstr. 74, 01307 Dresden, Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esomeprazole

Start the discussion